Why GLP-1?

Trusted brands in one place
Clinically proven for weight loss
Doctor-guided programs
No in-person appointments needed
Trusted brands in one place
Trusted brands in one place

Explore GLP-1's
News & Updates

Learn more about GLP'-1's latest news & updates

Explore By Category

All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Rosie O'Donnell Lost 60 Lbs on Mounjaro: What to Know
News & Updates

Rosie O'Donnell Lost 60 Lbs on Mounjaro: What to Know

Rosie O'Donnell recently shared she has lost nearly 60 pounds using Mounjaro since relocating to Ireland. Her story raises important questions about tirzepatide access, real-world results, and what patients in the US should know before starting this medication.

Read More
GLP-1 Medications and Endometriosis: What We Know
GLP-1 Agonists

GLP-1 Medications and Endometriosis: What We Know

GLP-1 medications like semaglutide and tirzepatide are best known for weight loss, but emerging research suggests they may also reduce the inflammation and pain associated with endometriosis. This article breaks down what we currently know, what's still uncertain, and how to talk to your doctor about it.

Read More
Oral Semaglutide: What US Patients Should Know
GLP-1 Agonists

Oral Semaglutide: What US Patients Should Know

Novo Nordisk is advancing an oral version of semaglutide toward the US market, raising big questions for current and prospective GLP-1 patients. This article breaks down what oral semaglutide means for access, affordability, and your treatment options going forward.

Read More
GLP-1 and Hair Loss: What You Need to Know
Health and Wellness

GLP-1 and Hair Loss: What You Need to Know

Hair loss is one of the more surprising side effects reported by people taking GLP-1 medications like semaglutide and tirzepatide. This article explains why it happens, what the research actually shows, and what practical steps you can take if you notice thinning hair during your weight loss journey.

Read More
Rybelsus Rebranded as the Ozempic Pill: What It Means
News & Updates

Rybelsus Rebranded as the Ozempic Pill: What It Means

Novo Nordisk is rebranding Rybelsus, its oral semaglutide tablet, under the Ozempic name. This move has real implications for patients comparing GLP-1 options. Here is what you need to know before your next provider conversation.

Read More
FDA Cracks Down on Compounded GLP-1s: What It Means for You
News & Updates

FDA Cracks Down on Compounded GLP-1s: What It Means for You

The FDA is taking action to limit compounded versions of popular GLP-1 medications like semaglutide and tirzepatide, citing safety concerns. If you're currently using a compounded GLP-1 or weighing your options, this shift has real implications for your treatment plan and your wallet. Here's what you need to know.

Read More
Louisiana Medicaid May Cover Ozempic and Wegovy
News & Updates

Louisiana Medicaid May Cover Ozempic and Wegovy

A new bill in Louisiana could open Medicaid coverage for GLP-1 medications like Ozempic, Wegovy, and Mounjaro. For low-income residents who've been priced out of these treatments, the stakes are high. Here's what the proposal means, who it could help, and what to do while you wait.

Read More
GLP-1 Drugs and Hair Loss: What You Need to Know
GLP-1 and Hair Loss

GLP-1 Drugs and Hair Loss: What You Need to Know

A new study from UCSF has found a connection between GLP-1 weight loss medications and hair loss. Here is what the research actually shows, why it happens, and practical steps you can take if you are experiencing shedding while on semaglutide or tirzepatide.

Read More
FDA Moves to Block Compounded GLP-1s: What It Means for You
News & Updates

FDA Moves to Block Compounded GLP-1s: What It Means for You

The FDA has proposed excluding the active ingredients in popular GLP-1 obesity and diabetes medications from the list of substances eligible for compounding. This move could cut off access to lower-cost compounded versions for millions of patients. Here is what you need to know and what steps to consider now.

Read More